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Myocardial regeneration is one of the most promising
therapeutic strategies for heart failure patients. Many ex-
perimental studies have demonstrated that different types
of stem cell can differentiate into myocardial cells and tis-
sues necessary for regeneration of the damaged myocar-
dium, while studies in experimental animals suggest that
muscle (myoblast), bone marrow (mesenchymal, endot-
helial or hematopoietic progenitors) and even heart cells
can help to improve heart contractility in vivo. These fin-
dings have led several groups to undertake studies in pa-
tients with myocardial infarction. However, the use of ce-
llular therapy in clinical trials is not without controversy,
mainly related with the need for better knowledge before
these therapeutic strategies are used in clinical practice.
Although significant enhancement of our knowledge of
the processes involved is fundamental, we do not consi-
der it unreasonable to initiate clinical trials in which speci-
fic questions are posed, whose answers will allow us to
make further progress. 
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The use of cells for tissue regeneration or repair is
one of the most promising areas in biomedical rese-
arch. The idea of regenerative medicine based on the
use of the patient’s own cells is attracting increasing
interest.1 However, only very preliminary trials are in
progress and the translation of these strategies into cli-
nical practice is still some way ahead. We present a
perspective of the current state of heart cell regenera-
tive therapy based on the recent experience of several
groups involved in this field, and identify some of the
main issues. 
STEM CELLS AND CARDIOMYOCYTES 
Different types of stem cells, both in embryonic
and adult tissues, are able to proliferate and produce
mature functional cells. Embryonic stem cells can
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Utilización de células madre para la regeneración
miocárdica en la insuficiencia cardíaca.
La terapia celular en la reparación miocárdica se
vislumbra como una de las estrategias terapéuticas con
mayor futuro en el tratamiento de la insuficiencia
cardíaca. Numerosos estudios in vitro recientes apoyan
la potencialidad de distintos tipos de células madre de
diferenciarse hacia los tejidos necesarios para regenerar
el tejido miocárdico dañado, mientras que estudios en
animales de experimentación sugieren que células madre
de músculo (mioblastos), médula ósea (progenitores
mesenquimales, endoteliales o hematopoyéticos) e
incluso del propio corazón pueden contribuir in vivo a
mejorar la contractilidad cardíaca. Estos trabajos han
conducido a que diversos grupos hayan iniciado estudios
en pacientes con infarto de miocardio. Sin embargo, la
utilización de la terapia celular en ensayos clínicos no
está desprovista de controversia, fundamentalmente
relacionada con la necesidad de aumentar nuestro
conocimiento antes de pasar a la aplicación clínica de
estas estrategias terapéuticas. Aunque es fundamental
aumentar significativamente el conocimiento de los
procesos, no consideramos irrazonable iniciar ensayos
clínicos en los que se identifiquen preguntas concretas
cuya respuesta nos permita avanzar en esta dirección.
Palabras clave: Insuficiencia cardíaca. Células madre.
Mioblastos. Regeneración cardíaca.
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differentiate into almost any of the more than 200 tis-
sues existing in an adult organism. Within the diffe-
rent organs are pluripotential stem cells able to diffe-
rentiate into functional tissues, such as liver stem
cells (oval cells), nerve stem cells, muscle stem cells,
and gastrointestinal or bone marrow stem cells.
Although still controversial, evidence suggests that
certain adult stem cells are much more pluripotential
than originally thought, and may also give rise to
most adult tissues.2-6
The possibility of obtaining muscle and endothelial
tissue from stem cells, together with the high inciden-
ce of patients with heart failure, the limited efficacy of
medical treatment and the lack of available organs for
heart transplants have led to the application of stem
cell therapy for the treatment of patients with heart fai-
lure, mainly of ischemic origin.7-11
Embryonic stem cells 
Despite the fact that embryonic stem cells can diffe-
rentiate into cardiomyocytes and regenerate myocar-
dium,12 their application has been restricted to experi-
mental animal studies because of their immunogenic
potential,13 the possibility of generating tumors in
vivo, their potential to cause arrhythmia,14 and certain
ethical issues. 
Cardiac stem cells 
As has happened with nerve cells, the traditional
view that cardiomyocytes are unable to proliferate has
had to be revised as a result of several recent studies,
which demonstrate the existence in the human heart of
cells with proliferative capacity.15,16 It is not known
whether these cells are indeed present in the heart
(cardiac stem cells in the atrium), or whether they de-
rive from other adult tissues such as bone marrow.17
Although these studies are of great biological interest,
they seem unlikely to have important clinical reper-
cussions for patients with myocardial infarction.18
Nevertheless, the possibility of stimulating the migra-
tion and proliferation of stem cells in vivo is of great
therapeutic interest. Recent studies in animal models
given growth factors suggest that it may be possible to
stimulate heart regeneration by «mobilizing» these
stem cells.19
Bone marrow stem cells 
Stem cells derived from bone marrow have shown
the greatest ability to differentiate into heart muscle
fibers or endothelial cells, thereby contributing to an-
giogenesis or vasculogenesis.7,20-24 Unlike those stu-
dies in which mononuclear bone marrow cells were
used,20 work by Anversa and Orlic’s group used se-
lected enriched populations of hematopoietic bone
marrow stem cells. They demonstrated that intracar-
diac injection of Lin– Kit+ cells into the infarction
scar in a rat model of infarction induces colonization
of the scar by cardiomyocytes and vascular structures
derived from the implanted cells.23 This regeneration
was accompanied by improved cardiac function and
increased survival of the animals. In addition to he-
matopoietic stem cells, bone marrow contains endot-
helial stem cells able to contribute to neo-angiogene-
sis, favoring myocardial regeneration.24-26 The
systemic administration of these cells in infarction
models helped to improve cardiac function24 as a re-
sult of increased vasculogenesis in the infarcted area,
reduced cardiomyocyte apoptosis and improved con-
tractility. Endothelial stem cells, however, do not 
acquire the characteristics of heart muscle.
Mesenchymal stem cells from bone marrow are able
to differentiate into mesodermal tissues such as oste-
oblasts, chondrocytes, adipocytes or skeletal mus-
cle.27 Recent studies even indicate that mesenchymal
stem cells are able to differentiate into cardiomyocy-
tes both in vitro and in vivo.20,28 Using animal models
of infarction, several groups have shown that me-
senchymal stem cells injected into the myocardial
scar are not only able to engraft but also acquire the
characteristics of cardiomyocytes, and more impor-
tantly, contribute to improved cardiac function.20,29 A
subpopulation of pluripotential mesenchymal stem
cells called MAPC was recently described as able to
differentiate into tissues derived from any of the th-
ree embryonic layers.5,30
Muscle stem cells
In addition to bone marrow or cardiac stem cells,
muscle stem cells (satellite cells or skeletal myo-
blasts), which are precursors of muscle fibers, may
also have practical applications as they possess un-
doubted muscular potential.31 The possibility of in vi-
tro expansion of the number of muscle progenitor cells
has made studies in animal models of infarction possi-
ble. Implanted myoblasts were able to engraft and ter-
minate the differentiation process into muscle fibers,
thereby contributing to improved cardiac function and
survival of the animals.32,33 Myoblasts can be adminis-
tered not only by intracardiac injection but also percu-
taneously,34,35 since they are able to migrate via the mi-
crocirculation and integrate into the interstitium. One
of the main disadvantages of muscle stem cells is their
inability to acquire the necessary characteristics of he-
art muscle to enable transmission of the electromecha-
nical stimulus, and thereby improve myocardial func-
tion.33,36,37
Experimental in vitro and in vivo studies with ani-
mals undoubtedly support the existence of stem cells
able to contribute to improved cardiac function.
However, numerous questions still remain and efforts
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must be made to provide answers which justify thera-
peutic studies of these treatments. Stem cells clearly
exist with endothelial, cardiac and muscle potential,
but it is necessary to identify these cells and determine
which signals are required to develop this potential, as
well as the signals required to ensure that their poten-
tial is developed in harmony with their surrounding
tissues, avoiding loss of functionality.
CLINICAL EXPERIENCE IN REGENERATIVE
CARDIAC THERAPY
Despite the many unknowns, results accumulated
over recent years from preclinical trials have led to
the first clinical trials of the feasibility and safety of
cardiac regeneration with stem cells. These trials have
often been accompanied by a certain degree of con-
troversy, owing to the opinion of researchers who ar-
gue that evidence is insufficient to justify clinical re-
search. Seven clinical trials have so far been
published7-11,38,39 on the use of percutaneous, intracavi-
tary or intramyocardial infusion of bone marrow–de-
rived mononuclear cells and cells enriched in hemato-
poietic, endothelial or myoblast progenitor cells. The
results were monitored by function and imaging tech-
niques such as magnetic resonance imaging, echocar-
diography or positron emission tomography. Control
groups have occasionally been used to compare re-
sults between patients either receiving or not recei-
ving cells, but in all cases the patients also received
additional therapy. 
Menasché et al pioneered the use of skeletal myo-
blasts and carried out the first implant of autologous
myoblasts in a patient with an infarction in June
2000.40 Their strategy consisted of obtaining a muscle
biopsy 2-3 weeks before revascularization surgery in
patients with an old infarction and non-viable myocar-
dial tissue in the area. After in vitro culture the cells
are then implanted by intra-myocardial injection into
the peri-infarction area during surgery. Results from
the first ten patients who underwent this treatment
were recently published.11 They suggest improved car-
diac function with a significant increase in ejection
fraction. However, despite the fact that the cells were
injected into non-revascularized areas, it is impossible
to determine with certainty whether the effect was due
to the bypass surgery or the implantation of myoblasts.
Notably, four of the ten patients included in the study
had ventricular arrhythmia (ventricular tachycardia)
which required implantation of a defibrillator. This
suggests that treatment with myoblasts may induce 
arrhythmias.39
Other groups have used mononuclear bone marrow
cells instead of myoblasts.8,10 Strauer et al used coro-
nary angiography to inject mononuclear bone ma-
rrow cells into patients with acute myocardial infarc-
tion at the same time as they inserted a coronary
stent, during the immediate post-infarction period.8
Their control group was composed of 10 patients
who underwent the same therapeutic procedure ex-
cept for cell injection. Ten weeks after treatment the
size of the infarction was reduced, and there were in-
creases in ejection fraction, cardiac index and systo-
lic volume in the treatment group compared to the
control group. This improvement in ventricular func-
tion was attributed to increased myocardial perfusion
as measured by radioisotope studies. In the study by
Tse et al, 8 patients with severe ischemic heart 
disease received mononuclear bone marrow cells via
intracardiac catheter guided by electromechanical
mapping.10 The improvements in cardiac perfusion
and function were determined by cardiac magnetic
resonance imaging. 
Injections of bone marrow progenitor cells enriched
with endothelial progenitor cells have also been given,
with the aim of inducing increased angiogenesis and
vasculogenesis in the infarcted tissue, to improve car-
diac function and reduce apoptosis and ventricular re-
modeling.7,9 These 2 studies, however, differed in tre-
atment indication and in type of implanted cells. In the
German study,7 20 patients with infarction in the acute
phase undergoing reperfusion received intracoronary
infusion of a heterogeneous population of cells, inclu-
ding a high percentage of peripheral blood endothelial
or bone marrow progenitor cells cultured for four days
in vitro. Patients who received cell therapy showed
improved regional contractility as measured by echo-
cardiography. Increased viability of the infarcted re-
gion was also demonstrated by positron emission to-
mography.7 Stamm et al have recently reported the use
of AC133 cells purified from the bone marrow of pa-
tients with an old infarction. A group of six patients
underwent aortocoronary bypass surgery during which
they received 1.5 × 106 AC133 cells directly into the
peri-infarcted myocardium.9 As with the other studies,
there was an increase in cardiac contractility and per-
fusion of the infarcted area, as measured by radioiso-
tope studies.
CONCLUSIONS
Despite the numerous experimental and clinical stu-
dies published to date, it still remains difficult to draw
definitive conclusions. The interest in the use of cell
therapy for heart failure is a result of expectations ge-
nerated by this type of treatment. Nevertheless, the
complexities of cell biology make great caution neces-
sary when interpreting the results of this type of the-
rapy, prior to clinical application. An additional aspect,
which for reasons of space we are unable to discuss
further, is the role of imaging techniques in determi-
ning the therapeutic benefit of this type of treatment.41
Technical advances play an important role in desig-
ning clinical and experimental studies. 
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Perhaps the most important message here is the need
for continued research in this field, and the need to fa-
cilitate multidisciplinary collaboration to enable some
of the remaining questions to be answered. For exam-
ple, what is the ideal source of stem cells? Do the dif-
ferent types of cell produce benefits in different situa-
tions?  How many cells is it necessary to implant?
What is the best route for stem cell administration
—percutaneous, direct intracardiac injection, or intra-
venous? What are the indications for cell therapy in
heart disease, i.e., is it better to administer the cells du-
ring the acute phase or in old infarctions? Can this the-
rapy be used in the treatment of dilated cardiomyo-
pathy? As we can see, there are far more questions
than answers. We are facing a stimulating panorama in
a completely new field which will doubtless lead to
solutions and contribute to decisive improvements in
therapy. 
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